GlassScriptPhysician profile
Raquel Guevarra
NPI 1366942229
$2,304.03
in general payments reported to CMS, 2019-2025
20 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $87.43 · 2022: $134 · 2023: $465 · 2024: $1,199 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $381.37 | 2021-2025 | Gardasil 9, Vaxneuvance, Rotateq |
| Cranial Technologies, INC | $325.56 | 2022-2025 | Doc Band |
| Regeneron Healthcare Solutions, INC. | $268.39 | 2024-2025 | Dupixent |
| Novo Nordisk INC | $215.97 | 2023-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $163.72 | 2023-2024 | Caplyta |
| Exact Sciences Corporation | $126.97 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $118.71 | 2024 | |
| Sanofi Pasteur INC. | $117.39 | 2022-2024 | |
| Dexcom, INC. | $109.98 | 2023 | Dexcom G6 Transmitter |
| Genzyme Corporation | $93.14 | 2023-2025 | |
| Hologic Sales and Service, LLC | $58.51 | 2021-2024 | Aptima, Thinprep 2000 Processor |
| Glaxosmithkline, LLC. | $49.71 | 2021-2024 | Pediarix, Rotarix, Bexsero |
| Antares Pharma, INC. | $49.50 | 2024 | Xyosted |
| Pfizer INC. | $47.96 | 2024 | |
| Aurinia Pharma U.S., INC. | $46.20 | 2023-2024 | Lupkynis |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $33.39 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.20 | 2022 | |
| Lilly USA, LLC | $27.75 | 2025 | Mounjaro |
| Cipher Pharmaceuticals US LLC | $23.86 | 2025 | Natroba, Spinosad |
| Ultragenyx Pharmaceutical INC. | $16.75 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Guevarra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.